Modern 09.30 NASDAQ: MRNA + 3.5% hours later, as the results of a phase 1 study showed that the mRNA-1273 candidate for the coronavirus vaccine was well tolerated and generated a strong immune response in adult adults.
The vaccine, which was developed jointly by researchers at Moderna and the National Institute of Allergy and Infectious Diseases, produces viral neutralizing antibodies at levels similar to those seen in younger adults, with side effects roughly equal to high-dose flu vaccines. , according to a study published in New England Journal of Medicine.
The findings are reassuring because immunity tends to weaken with age, Dr. Evan Anderson, one of the lead researchers at Emory University, told Reuters.
Swiss contract maker Lonza said today that it is confident that its plants in the United States and Switzerland will be ready to produce commercial quantities of mRNA-1